← Holdings
CLBT

CELLEBRITE DI LTD

2 managers · $154M total
Data: SEC EDGAR 13F · 2026Q1
Manager holders · last 4 qtrs
2
2025Q2 – 2026Q1 · flat QoQ
Total position
$154M
Combined value across tracked managers
Net move this quarter
↑ Adding
Weighted by holders' share change
HolderQ actionValue% of port.Style
VossAdd+20.19%$133M7.07%GARP / Growth-Value blend
Greenhaven RoadTrim-4.04%$21M14.55%SMID Value / Contrarian
What managers say
2026-03-31Voss CapitalBullVoss Capital Q1 2026 Letter to PartnersDetail →
2025-12-31Voss CapitalBullVoss Capital Q4 2025 Letter to PartnersDetail →
2025-12-31Greenhaven Road CapitalBullGreenhaven Road Capital Q4 2025 Investor LetterDetail →
2025-09-30Voss CapitalBullVoss Capital Q3 2025 Letter to PartnersDetail →
2025-09-30Greenhaven Road CapitalBullGreenhaven Road Capital Q3 2025 Investor LetterDetail →
Earnings Calls
Q1 2026May 14, 2026
This quarter’s performance met expectations, primarily driven by strong market reception for AI products such as Genesis, despite net new ARR remaining flat year-over-year. Long-term growth momentum remains robust.
Key Data: Q1 net new ARR was $12.2 million (flat YoY); Genesis product has attracted over 500 registered users; management estimates the total addressable market for AI products at $12.5 billion.
Business Progress: During the quarter, the company launched the Genesis AI investigation platform and Advanced Unlock technology, the latter going live in the last ten days of the quarter and quickly generating demand. Genesis has already helped resolve several high-profile cases (e.g., counter-terrorism, child protection), compressing efficiency from weeks to minutes. Meanwhile, the U.S. federal business is seeing the largest transaction opportunity in history, driven by a warming budget environment and advantages from ATOs certifications. Customers are shifting from point solutions to platform-based partnerships.
Guidance & Outlook: Management has not adjusted its full-year guidance but is optimistic about the adoption pace of products like Genesis, suggesting it may outpace industry averages. The report maintains a conservative assumption of approximately $600 million in full-year ARR and emphasizes that federal earmarks (over $30 million) will drive growth in the second half of the year.
Risk/Positive Signals: Positive signal — management is highly enthusiastic about the Genesis product, stating "once used, never abandoned," and customer feedback indicates real case resolutions. Negative signal — Q1 net new ARR was flat YoY, partly due to budget delays and seasonality, but management believes no deals were lost.
Q4 2026February 11, 2026
Financials
Financials coming soon — 10-K data not yet synced for this name